Loading…
← CockpitCompetitor Analysis › LQDA Liquidia CorporationOpen in the cockpit ↗

Liquidia CorporationLQDACompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Biotech selling an inhaled treprostinil therapy (Yutrepia) for pulmonary hypertension, competing with United Therapeutics.

Momentum strong 72
Mkt cap
$5.08B
US dollars, full cap
Free float
87%
of shares outstanding
$/day
$128M
20-day average traded
Fwd P/E
13.8×
forward earnings
ROIC−WACC
n/a
WACC 7.0%
Hurdle
-187 pp
Req g minus delivered
Next earnings
120 days
18 Mar 2027
Close · USD$56.40
1D-0.6%
1W+2.2%
1M+55.2%
3M-20.6%
6M-8.7%
YTD+63.5%
1Y+98.6%
ATR %6.5%
Beta0.85
52w lowhigh39.8% off high

What Liquidia does

Biotech selling an inhaled treprostinil therapy (Yutrepia) for pulmonary hypertension, competing with United Therapeutics.

Yutrepia reached the market in 2025 after FDA approval, so the company is moving from development to selling its own drug. Sales run through specialty pharmacies, which supply patients with this class of drug. United Therapeutics, which sells rival treprostinil products, has contested its patents.

Products and services

  • Yutrepia (inhaled treprostinil)
  • PRINT drug-particle technology

Customers

  • Pulmonologists/cardiologists
  • Health systems
  • Payers

Where it sits in the supply chain

  • Pharmaceuticals
  • Biotech
  • Pulmonary hypertension

What could go right

  • Yutrepia share gains in pulmonary arterial hypertension
  • Litigation resolution clearing full launch

What could go wrong

  • Ongoing patent litigation with United Therapeutics
  • Single-product revenue concentration

Moat: narrow (IP / patents, process know-how). Proprietary dry-powder particle-engineering technology differentiates its inhaled treprostinil from liquid rivals.

Headquarters: Morrisville, North Carolina, United States · Founded: 2004 · Employees: 216

Named competitors

Liquidia at a glance

Size Liquidia (LQDA) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $5.08B, the 1165th largest of 3,085 United States companies the cockpit tracks. Shares closed at $56.40 on 18 Nov 2026.

Performance Over six months the shares fell 8.7%, against +10.6% for the median peer and -2.2% for the United States market (cap-weighted) — 7th lowest of 21 in its peer set.

Growth Revenue grew 798.4% over the last twelve months (peer median +11.3%); the operating margin is 47.1% (peer median 20.6%).

Valuation It trades at 13.8× forward earnings against a peer median of 28.7× (4th cheapest of 18).

Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +192%, so the hurdle is -187 pp: the price already allows for a slowdown.

Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).

Relative performance

5010015021 May 202621 Aug 202618 Nov 2026Peer median 112LQDA 91
Six months, rebased to 100: Liquidia against the median of its 20 peers (local-currency closes).

Liquidia financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$622M$158M$14.0M$17.5M$15.9M
Revenue growth—+1,031%-20%+10%—
Gross profit$576M$144M$6.82M$13.4M$11.3M
EBITDA$295M-$49.8M-$119M-$71.2M-$34.8M
Net income-$94.2M-$68.9M-$128M-$78.5M-$41.0M
Free cash flow$291M-$40.0M-$98.4M-$42.9M-$29.2M
Capital expenditure$33.0M$4.34M$4.95M$1.29M$592,000
Total debt$169M$198M$120M$3.50M$24.5M

Quarterly statements and history in the cockpit →

Liquidia competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%0%+20%+40%326030PTCTIPCALAB600085MANE600079ERASTVTXGLAXOEMCURE603087IONSGLAND0874ABBOTINDIAAJANTPHARM600566CAMXLQDA6-month return →1-month return →
Up and to the right = strong over both horizons. Liquidia is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%+600%+800%20×40×326030PTCTIPCALAB6000856000796885784506TVTXGLAXOEMCUREGLAND0874CAMXLQDARevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Liquidia is the large dot.

Capital: growth delivered against growth the price implies

0%+200%+400%0%200%400%326030PTCTIPCALAB600079688578LQDAGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Liquidia is the large dot.

Liquidia competitors and peer comparison

Head to head with its named competitors (LQDA vs UTHR vs MRK vs JNJ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Liquidia LQDA$5.08B-9%+798%47%13.8×5.0%
United Therapeutics UTHR$24.6B+2%+2%44%23.9×0.3%
Merck & MRK$340B+23%+5%18%16.4×8.3%
Johnson & Johnson JNJ$656B+20%+8%26%24.2×3.7%
Insmed INSM$26.3B+3%+240%-42%n/an/a
Gossamer Bio GOSSn/a-34%n/an/an/an/a

How Liquidia compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Liquidia against its 20 peers (data as of 18 Nov 2026)
MeasureLQDAPeer medianRank in peer set
1-month return+55.2%-1.2%highest of 21
6-month return-8.7%+10.6%7th lowest of 21
Distance from 52-week high-39.8%-21.1%6th lowest of 21
Revenue growth (TTM)+798.4%+11.3%highest of 19
Operating margin47.1%20.6%highest of 19
Forward P/E13.8×28.7×4th cheapest of 18
Growth the price implies (Req g, 7 yrs)5.0%7.3%8th least demanding of 17
Growth delivered (Del g)+192.5%+12.5%2nd highest of 17
Hurdle (Req g minus delivered)-187.4 pp-2.6 pp2nd least demanding of 17
EV / EBITDA16.5×22.8×3rd cheapest of 11
Net debt / EBITDA-0.8×-0.7×6th least indebted of 12

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Liquidia LQDAUnited States$5.08B-9%+798%47%13.8×5.0%+192.5%
SKBP 326030.KSSouth Korea$5.03B-16%+37%38%21.5×-4.4%+93.6%
PTC Therapeutics PTCTUnited States$5.03B-15%-35%22%31.2×6.6%+35.4%
IPCA Laboratories IPCALAB.NSIndia$5.03B+12%+12%18%31.1×16.5%+12.2%
Beijing TongRenTang 600085.SSChina$4.91B-12%-17%8%28.7×1.7%+6.2%
Veradermics MANEUnited States$5.27B+19%n/an/an/an/an/a
Humanwell Healthcare (Group) 600079.SSChina$4.87B+11%+2%15%13.8×-8.8%+3.0%
Shanghai Allist Pharmaceuticals 688578.SSChina$5.32B-14%+39%47%12.4×0.1%+519.6%
Sumitomo Pharma 4506.TJapan$5.33B+11%+11%10%8.6×1.7%-2.6%
Erasca ERASUnited States$4.83B+24%n/an/an/an/an/a
Travere Therapeutics TVTXUnited States$4.82B+16%+49%-3%17.1×17.3%+19.9%
GlaxoSmithKline Pharmaceuticals GLAXO.NSIndia$4.79B+10%+12%33%37.3×26.4%+5.5%
Emcure Pharmaceuticals EMCURE.NSIndia$4.74B+37%+21%16%33.6×15.9%+12.7%
Gan & Lee Pharmaceuticals 603087.SSChina$5.59B+11%+14%20%25.8×n/an/a
Ionis Pharmaceuticals IONSUnited States$4.56B-64%-1%-59%n/an/an/a
Gland Pharma GLAND.NSIndia$5.71B+44%+22%21%39.3×20.2%+13.3%
Guangzhou Baiyunshan Pharmaceutical 0874.HKHong Kong$4.48B-23%+6%3%7.0×1.3%+4.0%
Abbott India ABBOTINDIA.NSIndia$5.80B-8%+7%28%31.1×8.0%+10.0%
Ajanta Pharma AJANTPHARM.NSIndia$4.38B+1%+25%25%31.7×23.8%+13.8%
HUBEI JUMPCAN PHARMACEUTICAL 600566.SSChina$4.36B+12%-4%32%16.2×-9.9%+0.3%
Camurus CAMX.STSweden$4.36B+36%+3%38%45.1×7.9%+46.5%

Questions

Who are Liquidia's main competitors?
Named competitors: United Therapeutics (UTHR), Merck (MRK), Johnson & Johnson (JNJ), Insmed (INSM), Gossamer Bio (GOSS). The cockpit's measured peer set (industry) also includes SKBP (326030.KS), PTC Therapeutics (PTCT), IPCA Laboratories (IPCALAB.NS), Beijing TongRenTang (600085.SS), Veradermics (MANE), Humanwell Healthcare (Group) (600079.SS).
Is Liquidia expensive compared with its peers?
On forward p/e it trades at 13.8× against a peer median of 28.7×, 4th cheapest of 18 in its peer set. For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +192%, so the hurdle is -187 pp: the price already allows for a slowdown.
How has Liquidia stock performed?
Over six months to 18 Nov 2026 the shares returned -8.7% against +10.6% for the median peer; over one year +98.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.